Abstract:Abstract Tumor growth is intricately linked to the process of angiogenesis, with a key role played by vascular endothelial growth factor (VEGF) and its associated signaling pathways. Notably, these pathways also play a pivotal “housekeeping” role in renal physiology. Over the past decade, the utilization of VEGF signaling inhibitors has seen a substantial rise in the treatment of diverse solid organ tumors, diabetic retinopathy, age-related macular degeneration, and various ocular diseases. However, this increased use of such agents has led to a higher frequency of encountering renal adverse effects in clinical practice. This review comprehensively addresses the incidence, pathophysiological mechanisms, and current evidence concerning renal adverse events associated with systemic and intravitreal antiangiogenic therapies targeting VEGF-A and its receptors (VEGFR) and their associated signaling pathways. Additionally, we briefly explore strategies for mitigating potential risks linked to the use of these agents and effectively managing various renal adverse events, including but not limited to hypertension, proteinuria, renal dysfunction, and electrolyte imbalances.

What problem does this paper attempt to address?

The paper primarily explores the critical role of Vascular Endothelial Growth Factor (VEGF) and its related signaling pathways in tumor growth, with a particular focus on the application of VEGF inhibitors in the treatment of various diseases and the resulting renal adverse effects. Specifically, the paper attempts to address the following issues: 1. **The role of VEGF in physiological and pathological processes**: The paper first elucidates the importance of VEGF in diseases such as tumor growth and diabetic retinopathy, pointing out that VEGF is not only a key factor in promoting angiogenesis but also plays an important role in maintaining kidney function. 2. **Application and efficacy of VEGF inhibitors**: In recent years, VEGF signal inhibitors have been widely used to treat various solid tumors, diabetic retinopathy, age-related macular degeneration, and other ophthalmic diseases. These drugs effectively inhibit abnormal angiogenesis by targeting VEGF and its receptors (such as VEGFR), improving patient survival rates and quality of life. 3. **Mechanisms of renal adverse effects**: However, with the widespread use of VEGF inhibitors, an increasing number of renal side effects have been observed in clinical practice, including hypertension, proteinuria, renal insufficiency, and electrolyte imbalances. The paper provides a detailed analysis of the pathophysiological mechanisms of these adverse effects, emphasizing the critical role of VEGF in maintaining the structural integrity of the glomerulus. 4. **Existing evidence and management strategies**: Based on current research findings, the paper summarizes epidemiological data on renal adverse effects caused by VEGF inhibitors, early biomarker detection methods, and strategies to effectively manage and mitigate these side effects. Additionally, it discusses methods for identifying high-risk patients, specific measures during monitoring, and potential preventive approaches. In summary, the paper aims to comprehensively review and update the existing knowledge on VEGF inhibitor-induced renal toxicity, with the goal of providing more guidance for clinical practice.

Ocular and systemic vascular endothelial growth factor ligand inhibitor use and nephrotoxicity: an update

Exploring the Spectrum of VEGF Inhibitors' Toxicities from Systemic to Intra-Vitreal Usage in Medical Practice

Membranoproliferative glomerulonephritis after intravitreal vascular growth factor inhibitor injections: A case report and review of the literature

Vascular endothelial growth factor in eye disease

Progress of Anti-Vascular Endothelial Growth Factor Therapy for Ocular Neovascular Disease: Benefits and Challenges

Effect of intravitreal anti-endothelial growth factor agents on renal function in patients with Diabetes Mellitus.

Immunoregulation mechanism of VEGF signaling pathway inhibitors and its efficacy on the kidney

Do Intravitreal Anti-Vascular Endothelial Growth Factor Agents Lead to Renal Adverse Events? A Pharmacovigilance Real-World Study

Aflibercept (VEGF Trap): One More Double-Edged Sword of Anti-Vegf Therapy for Cancer?

Indirect blockade of vascular endothelial growth factor: the potential for eye disease therapy

Risk of renal damage associated with intravitreal anti-VEGF therapy for diabetic macular edema in routine clinical practice

[Intraocular Antiangiogenic Drugs in Clinical Application Advantages and Disadvantages].

Gene Therapy Intervention in Neovascular Eye Disease: A Recent Update

Acute Kidney Injury from Intravitreal Anti-vascular Endothelial Growth Factor Drugs: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Enhanced durability and evolution of retreatment criteria of intravitreal antivascular endothelial growth factor agents for diabetic macular edema

Clinical use of vascular endothelial growth factor receptor inhibitors for the treatment of renal cell carcinoma

An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma

The Use of Vascular Endothelial Growth Factor Inhibitors in Patients with Proliferative Diabetic Retinopathy

Advancements and emerging trends in ophthalmic anti-VEGF therapy: a bibliometric analysis

Vascular Endothelial Growth Factor and Diabetic Retinal Disease

Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor–Associated Hypertension and Vascular Disease